FDA Approves Vaccine for Hepatitis B
PreHevBrio is a three-antigen hepatitis B vaccine for adults in the United States. It is expected to be available in the first quarter of 2022.
The FDA has approved PreHevbrio, a recombinant vaccine for the prevention of hepatitis B in adults 18 years of age and older. PreHevbrio, developed by VBI Vaccines, contains the S, pre-S2, and pre-S1 HBV surface antigens, and is the only approved three-antigen hepatitis B virus vaccine for adults in the United States.
Chari Cohen, DrPH
“Having more vaccine options will help us effectively expand vaccine uptake, ensure more people are protected from hepatitis B infection, and reach the 2030 goal of eliminating hepatitis B in the United States,” Chari Cohen, DrPH, senior vice president of the Hepatitis B Foundation, said in a statement.
The approval is based on data from two phase 3 clinical studies, PROTECT and CONSTANT.
The pivotal studies compared PreHevbrio with GlaxoSmithKline’s Engerix-B, a single-antigen hepatitis B vaccine. Data from the PROTECT study showed that PreHevbrio elicited higher rates of seroprotection in all subjects. The most common adverse events in all age groups were injection site pain and tenderness, myalgia, and fatigue, all which generally resolved without intervention in one to two days.
The data were published from the PROTECT study in The Lancet Infectious Diseases in May 2021 and the CONSTANT study in JAMA Network Open in October 2021.
VBI expects to make PreHevbrio available in the United States in the first quarter of 2022.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Trump Impact on Medicare Drug Price Negotiations Uncertain
Published: January 22nd 2025 | Updated: January 22nd 2025Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Read More
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
January 21st 2025One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.
Read More
